Leserbrief
Bulevirtide (Hepcludex) for Chronic Hepatitis Delta: A Milestone Achievement Demanding Real-World Evaluation
Annals of Pharmacotherapy · 09.08.2026
DOI: 10.1177/10600280261476305 ↗Kurz gefasst
Leserbrief in der Zeitschrift Annals of Pharmacotherapy, online erschienen am 09.08.2026. Verfasst von Aun Muhammad Shoro und 1 weiteren Autor:innen. Die Arbeit nennt 8 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
ORCID-Profile: Aun Muhammad Shoro, Sufwan Ullah Khan
Zitieren
APA
Shoro, A. M., & Khan, S. U. (2026). Bulevirtide (Hepcludex) for Chronic Hepatitis Delta: A Milestone Achievement Demanding Real-World Evaluation. Annals of Pharmacotherapy. https://doi.org/10.1177/10600280261476305
Vancouver
Shoro AM, Khan SU. Bulevirtide (Hepcludex) for Chronic Hepatitis Delta: A Milestone Achievement Demanding Real-World Evaluation. Annals of Pharmacotherapy. 2026. doi:10.1177/10600280261476305
BibTeX
@article{Shoro2026,
author = {Shoro, Aun Muhammad and Khan, Sufwan Ullah},
title = {Bulevirtide (Hepcludex) for Chronic Hepatitis Delta: A Milestone Achievement Demanding Real-World Evaluation},
journal = {Annals of Pharmacotherapy},
year = {2026},
doi = {10.1177/10600280261476305}
}
EUVIMED